FINWIRES · TerminalLIVE
FINWIRES

New Zealand Shares Fall Amid Cautious Trading Ahead of US-Iran Peace Talks; New Zealand King Salmon Investments Lifts Fiscal 2026 Outlook

By

New Zealand shares ended lower on Friday as most Asian markets saw a sell-off as investors remained cautious despite the Israel-Lebanon ceasefire taking effect ahead of US-Iran peace talks.

The S&P/NZX 50 Index fell 1.2% or 160.4 points to close at 12,905.67.

US President Donald Trump has said that the next discussions between the US and Iran may take place over the weekend, according to a Thursday Reuters report.

In domestic news, New Zealand's electronic card spending rose 1.3% month over month to NZ$9.85 billion in March on a seasonally-adjusted basis, matching the 1.3% increase recorded in the previous month, according to data from Stats NZ.

Also, the average asking price for a property in Christchurch in March held steady over the past three years and remained lower than other main centers in New Zealand, data from realestate.co.nz showed.

Further, petrol and diesel prices in New Zealand increased by nearly 19% and 43%, respectively, in March compared with the previous month, according to a Stats NZ selected price index report.

Meanwhile, annual inflation in New Zealand is expected to slow by 0.2 percentage points in the March quarter to 2.9%, slightly higher than the previous forecast of 2.8% but slightly lower than the Reserve Bank of New Zealand's (RBNZ) April forecast of 3%, ANZ Research said in a note.

In corporate news, New Zealand King Salmon Investments (NZE:NZK, ASX:NZK) upgraded its fiscal 2026 guidance, now expecting pro-forma earnings before interest, taxes, depreciation, and amortization of NZ$19 million to NZ$27 million, up from NZ$9 million to NZ$15 million.

Contact Energy (NZE:CEN, ASX:CEN) has applied to quote about 5 million ordinary shares issued in connection with its acquisition of an additional stake in King Country Energy.

Related Articles

Asia

Netwealth's FUA Net Flows in Fiscal Q4 Likely to See Seasonal Step-up, Jarden Says

Netwealth Group's (ASX:NWL) funds under administration (FUA) net flows are likely to see a seasonal step-up in the fiscal fourth quarter, which would see the fiscal 2026 outcome tracking slightly ahead of its guidance range, Jarden said in a Thursday note.It raised its earnings-per-share forecasts by 0.1% for fiscal 2026, 1.5% for fiscal 2027, and 1.6% for fiscal 2028.Jarden also flagged the risk of higher cost growth due to the enforceable undertaking, regulatory scrutiny, and recent treasury consultations.The investment firm retained its neutral recommendation on Netwealth Group and raised the price target to AU$25.70 from AU$25.35.Netwealth Group's shares gained 1% in recent Friday trade.

ASX:NWL
Asia

CDL Hospitality REIT Issues Stapled Securities as Payment of Management Fee

CDL Hospitality REIT (SGX:J85) issued 5.5 million stapled securities to its manager, H-REIT Manager and HBT Trustee-Manager as payment of management fee for 2025, according to a Friday filing with the Singapore Exchange.Nearly 5 million stapled securities were issued to the H-REIT Manager at SG$0.8199 per security as 80% payment of its performance fee for 2025.Meanwhile, 535,179 securities were issued to HBT Trustee-Manager at SG$0.8199 per security as payment of 80% of performance fee for 2025.

SGX:J85
Asia

Syntara's Myelofibrosis Drug Candidate Shows 'Significant' Commercial Potential, Euroz Hartleys Says

Syntara's (ASX:SNT) Amsulostat drug candidate has a "unique" position in the myelofibrosis landscape and "significant" commercial potential, Euroz Hartleys said in a Thursday note.Myelofibrosis is a blood cancer characterized by scar tissue formation or fibrosis in the bone marrow.Dr Adam Craig, Syntara strategic adviser and an industry leader in myelofibrosis, noted Amsulostat's mechanism targeting fibrosis, with the potential as a disease-modifying therapy, rather than just a symptomatic treatment.Craig said that Amsulostat's safety profile differs from current therapies and is unaware of any other drug taking a similar approach.Additionally, Craig said that Amsulostat's mechanism requires time for effect, as fibrosis evolves gradually. Patient responses observed at six months are complemented by a continuing improvement over time.Euroz Hartleys reaffirmed its speculative buy recommendation and AU$0.22 price target on Syntara.Syntara shares fell 1% in afternoon trade on Friday.

ASX:SNT